Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionaut and AnalytiCon to develop novel anticancer compounds
Bionaut will provide a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel pathway reporter system to
Bionaut will provide a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel pathway reporter system to
Carboplatin is one of the most broadly used anticancer agents. The exclusivity for Bristol-Myers Squibb’s Paraplatin expired in 2004, after which generic versions of the product were approved.
These are the first targets to be selected for advancement in the strategic collaboration established last year between Celera Genomics and Abbott to discover, develop and commercialize therapies
The patent held for Zyprexa had been challenged by generics manufacturers Dr Reddy’s, Ivax Corp and Teva Pharmaceuticals. The ruling to uphold Lilly’s intellectual property, made in a
Following Cenes’ innovative research program that began in 2003, the two companies have been working together and have identified several series of novel compounds active against the clinically
Preliminary findings from two placebo-controlled human studies on two formulations of M.doc, a haemostatic agent for wound care, indicate that there were no adverse affects and no safety
D-63153 is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist. The trial will evaluate the efficacy of D-63153 as measured by its effects on clinical signs and symptoms
Out of 146,948 participants, the study identified a total of 413 cases of Parkinson’s disease. The purpose was to identify whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs)
There are several ways to restore normal blood sugar levels in diabetics, including administration of insulin or pancreas and islet transplantation. However, the former involves daily injections and
Delex is advancing AeroLEF, a proprietary technology for the treatment of acute and breakthrough pain, conditions that are common in cancer patients and underserved by existing technology. AeroLEF